NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On March 20, 2017, Nektar Therapeutics, a Delaware corporation
(Nektar), issued a press release (the Press Release) announcing
the results from the SUMMIT-07 Phase 3 efficacy study for
NKTR-181 in the treatment of patients with moderate to severe
chronic low back pain. A copy of the Press Release reporting
results from the Phase 3 Study is furnished herewith as Exhibit
99.1.
In the Press Release, Nektar announced that it would hold a
Webcast conference call on March 20, 2017 at 5:45 a.m. (Pacific
Time)/8:45 a.m. (Eastern Time) on March 20, 2017 to review the
results from the Phase 3 SUMMIT-07 study. This conference call is
accessible through a link that is posted on the home page and
Investor section of the Nektar website: http://www.nektar.com.
The information in this report, including the exhibit hereto, is
being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying exhibit
shall not be incorporated by reference into any filing with the
Securities and Exchange Commission made by Nektar Therapeutics,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
| Item9.01 | Financial Statements and Exhibits. |
| Exhibit Number | Description | |
| 99.1 |
Press Release titled NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain issued by Nektar Therapeutics on March 20, 2017. |
About NEKTAR THERAPEUTICS (NASDAQ:NKTR)
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company’s drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection). NEKTAR THERAPEUTICS (NASDAQ:NKTR) Recent Trading Information
NEKTAR THERAPEUTICS (NASDAQ:NKTR) closed its last trading session down -0.21 at 15.50 with 2,452,406 shares trading hands.
